Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.53 |
| ▸ | GABRP | O00591 | 6/20 | 0.53 |
| ▸ | GABRD | O14764 | 6/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.53 |
| ▸ | GABRE | P78334 | 6/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644378 | 0.92 | CYP1A2 (0.52) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL1644521 | 0.92 | POLB (0.70) | CYP1A2POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL197360 | 0.90 | CYP1A2 (0.50) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL8883054 | 0.89 | POLB (0.49) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL600789 | 0.89 | GABRA1 (0.49) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL7999648 | 0.89 | SIRT6 (0.52) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL31285451 | 0.89 | GABRA1 (0.49) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL991765 | 0.89 | POLB (0.49) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL30986210 | 0.89 | SIRT6 (0.52) | CYP1A2POLBGABRA1GABRG2GABRB3 | |
| SCHEMBL6201965 | 0.87 | POLB (0.47) | CYP1A2POLBGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2305641-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| EP-0773930-B1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LTD (GB) | 2000-10-11 | — | — | EP | disclosed |
| US-5843942-A | Aromatic amino ethers as pain relieving agents | ZENECA LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | CYP1A2 58/4885POLB 2799/4885GABRA1 1427/4885 |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | CYP1A2 1777/4885POLB 4796/4885GABRA1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.